These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20069241)

  • 1. Psychiatric manifestations in multiple sclerosis patients and multiple sclerosis in psychiatric patient.
    Fragoso YD; Brooks JB
    Arq Neuropsiquiatr; 2009 Dec; 67(4):1167-8. PubMed ID: 20069241
    [No Abstract]   [Full Text] [Related]  

  • 2. Glatiramer acetate: a novel therapeutic approach in Crohn's disease?
    Neesse A; Michl P; Kunsch S; Gress TM; Steinkamp M
    Inflamm Bowel Dis; 2009 Jan; 15(1):156-7. PubMed ID: 18626969
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    J Neurol; 2000 Sep; 247(9):713. PubMed ID: 11081814
    [No Abstract]   [Full Text] [Related]  

  • 4. Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate.
    Krečak I; Celić-Bunikić S; Skelin M; Lucijanić M; Verstovsek S; Kušec R
    Ann Hematol; 2022 Aug; 101(8):1885-1886. PubMed ID: 35461396
    [No Abstract]   [Full Text] [Related]  

  • 5. Extended use of glatiramer acetate (Copaxone) for MS.
    Greenstein JI
    Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
    [No Abstract]   [Full Text] [Related]  

  • 6. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost of delaying treatment in multiple sclerosis: what is lost is not regained.
    Zwibel H
    Neurology; 2002 Feb; 58(4):667; author reply 668. PubMed ID: 11865160
    [No Abstract]   [Full Text] [Related]  

  • 8. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate.
    Windhagen A; Maniak S; Marckmann S; Lindert RB; Heidenreich F; Blasczyk R
    J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):415-6. PubMed ID: 11181881
    [No Abstract]   [Full Text] [Related]  

  • 11. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.
    Bourdette D; Hartung D
    JAMA Neurol; 2015 Dec; 72(12):1411-3. PubMed ID: 26457848
    [No Abstract]   [Full Text] [Related]  

  • 12. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Richert ND
    Neurology; 2002 May; 58(9):1440-1; author reply 1441-2. PubMed ID: 12011306
    [No Abstract]   [Full Text] [Related]  

  • 13. A 29-year-old man with multiple sclerosis, 1 year later.
    Delbanco TL; Hartman EE
    JAMA; 1999 Jun 23-30; 281(24):2329. PubMed ID: 10386558
    [No Abstract]   [Full Text] [Related]  

  • 14. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease modifying treatment in multiple sclerosis.
    Fuller GN; Bone I
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.
    Weiner HL
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3333-5. PubMed ID: 10097037
    [No Abstract]   [Full Text] [Related]  

  • 19. Glatiramer acetate in the treatment of multiple sclerosis.
    Miller AE
    Neurol Clin; 2005 Feb; 23(1):215-31, viii. PubMed ID: 15661095
    [No Abstract]   [Full Text] [Related]  

  • 20. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.